Business Standard

Lupin to expand Vadodara facility

With estimated cost of Rs 270 cr; 1,480 tonnes per annum capacity to be added

Sohini Das  |  Ahmedabad 

Mumbai-based player Ltd, is all set to expand its Vadodara facility to make for cardiac, anti-infectives, anti-tuberculosis, neurology and other segments. The estimated project cost is around Rs  270 crore.

The Dabhasa plant of near Vadodara is one of the leading bulk drug manufacturing sites for the company. "The Dabhasa plant is one of our major active pharmaceutical ingredient manufacturing sites which also exports. It is a US Food and Drug Administration (USFDA) approved facility," informed a senior company official. Meanwhile, the company is planning to expand the unit to add more belonging to the categories of anti-cholesterol, cardiac, neuropathic, respiratory, anti-infectives among others. The company is a leading global manufacturer of anti-tuberculosis like Ethambutol Hydrochloride and Rifampicin.



A company spokesperson confirmed the development. "It is true that we are expanding our facility in Dabhasa, near Vadodara though we haven’t procured any additional land for the stated expansion. has been investing prudently in expanding our manufacturing operations by setting up new and expanding existing facilities to meet future demand. The company’s capital expenditure stood at Rs  487.1 crore for FY 2013."

According to a senior official in the state government, who confirmed the development, the project cost could be to the tune of Rs  270 crore, and the company proposes to make around eighty different varieties of at the Dabhasa plant. The additional capacity would be to the tune of 1,480 tonnes per annum.

According to data from the IMS Health, therapies like cardiac, anti-diabetics, respiratory, dermatological have clocked a healthy growth during 2013 calendar year.

While the neuro-CNS segment clocked a 9.6 per cent value growth in the Indian market, others like cardiac grew by 11.1 per cent, anti-diabetics by 19.1 per cent, respiratory by 11 per cent, dermatological by 17.7 per cent and gastro-intestinals by 10.2 per cent.

RECOMMENDED FOR YOU

Lupin to expand Vadodara facility

With estimated cost of Rs 270 cr; 1,480 tonnes per annum capacity to be added

With estimated cost of Rs 270 cr; 1,480 tonnes per annum capacity to be added Mumbai-based player Ltd, is all set to expand its Vadodara facility to make for cardiac, anti-infectives, anti-tuberculosis, neurology and other segments. The estimated project cost is around Rs  270 crore.

The Dabhasa plant of near Vadodara is one of the leading bulk drug manufacturing sites for the company. "The Dabhasa plant is one of our major active pharmaceutical ingredient manufacturing sites which also exports. It is a US Food and Drug Administration (USFDA) approved facility," informed a senior company official. Meanwhile, the company is planning to expand the unit to add more belonging to the categories of anti-cholesterol, cardiac, neuropathic, respiratory, anti-infectives among others. The company is a leading global manufacturer of anti-tuberculosis like Ethambutol Hydrochloride and Rifampicin.

A company spokesperson confirmed the development. "It is true that we are expanding our facility in Dabhasa, near Vadodara though we haven’t procured any additional land for the stated expansion. has been investing prudently in expanding our manufacturing operations by setting up new and expanding existing facilities to meet future demand. The company’s capital expenditure stood at Rs  487.1 crore for FY 2013."

According to a senior official in the state government, who confirmed the development, the project cost could be to the tune of Rs  270 crore, and the company proposes to make around eighty different varieties of at the Dabhasa plant. The additional capacity would be to the tune of 1,480 tonnes per annum.

According to data from the IMS Health, therapies like cardiac, anti-diabetics, respiratory, dermatological have clocked a healthy growth during 2013 calendar year.

While the neuro-CNS segment clocked a 9.6 per cent value growth in the Indian market, others like cardiac grew by 11.1 per cent, anti-diabetics by 19.1 per cent, respiratory by 11 per cent, dermatological by 17.7 per cent and gastro-intestinals by 10.2 per cent.
image
Business Standard
177 22

Lupin to expand Vadodara facility

With estimated cost of Rs 270 cr; 1,480 tonnes per annum capacity to be added

Mumbai-based player Ltd, is all set to expand its Vadodara facility to make for cardiac, anti-infectives, anti-tuberculosis, neurology and other segments. The estimated project cost is around Rs  270 crore.

The Dabhasa plant of near Vadodara is one of the leading bulk drug manufacturing sites for the company. "The Dabhasa plant is one of our major active pharmaceutical ingredient manufacturing sites which also exports. It is a US Food and Drug Administration (USFDA) approved facility," informed a senior company official. Meanwhile, the company is planning to expand the unit to add more belonging to the categories of anti-cholesterol, cardiac, neuropathic, respiratory, anti-infectives among others. The company is a leading global manufacturer of anti-tuberculosis like Ethambutol Hydrochloride and Rifampicin.

A company spokesperson confirmed the development. "It is true that we are expanding our facility in Dabhasa, near Vadodara though we haven’t procured any additional land for the stated expansion. has been investing prudently in expanding our manufacturing operations by setting up new and expanding existing facilities to meet future demand. The company’s capital expenditure stood at Rs  487.1 crore for FY 2013."

According to a senior official in the state government, who confirmed the development, the project cost could be to the tune of Rs  270 crore, and the company proposes to make around eighty different varieties of at the Dabhasa plant. The additional capacity would be to the tune of 1,480 tonnes per annum.

According to data from the IMS Health, therapies like cardiac, anti-diabetics, respiratory, dermatological have clocked a healthy growth during 2013 calendar year.

While the neuro-CNS segment clocked a 9.6 per cent value growth in the Indian market, others like cardiac grew by 11.1 per cent, anti-diabetics by 19.1 per cent, respiratory by 11 per cent, dermatological by 17.7 per cent and gastro-intestinals by 10.2 per cent.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard